Chidamide, a selective inhibitor targeting HDAC1, HDAC2, HDAC3, and HDAC10, has been approved for treating relapsed/refractory peripheral T cell lymphoma and hormone receptor-positive, HER2-negative breast cancer after endocrine therapy 31. Here, HDAC3 is linked to breast carcinoma.